Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Sexually transmitted disease

Gentamicin not appropriate as first-line treatment for gonorrhoea, researchers say

Research published in The Lancet has shown that while gentamicin may not be appropriate as a first-line treatment for gonorrhoea, it is may be a useful second-line option for some patients.

Neisseria gonorrhoeae causes gonorrhoea


Although gentamicin could not be recommended as a replacement first-line treatment for gonorhoea, researchers say it may be appropriate as a second-line option for patients who are unable to take ceftriaxone

Gentamicin is no more effective overall than ceftriaxone as a first-line treatment for gonorrhoea, but could be a useful alternative for some patients, researchers have said[1].

A study published in The Lancet (2 May 2019) involved 720 people aged 16–70 years presenting with uncomplicated genital, pharyngeal or rectal gonorrhoea who were randomly assigned to either intramuscular gentamicin 240mg or intramuscular ceftriaxone 500mg, plus oral azithromycin 1g.

The overall cure rate at two weeks was higher in the ceftriaxone group than the gentamicin group, at 98% versus 91%. However, in the 328 participants with genital gonorrhoea, the cure rate was similar between the two groups at 98% and 94%, respectively.

Ceftriaxone is the current first-line treatment for gonorrhoea; however, resistant cases are beginning to emerge, leading to a need for alternatives.

The researchers said that they were unable to conclude that gentamicin was non-inferior to ceftriaxone and therefore could not recommend it as a replacement first-line treatment. However, they said it could be appropriate in genital gonorrhoea for patients allergic or intolerant to ceftriaxone, or those who have ceftriaxone-resistant infection.

“Further research is required to identify and test new alternatives to ceftriaxone for the treatment of gonorrhoea,” they concluded.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2019.20206586

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now
  • Pathology and Therapeutics for Pharmacists

    Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

    £54.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Popular Medicines

    Popular Medicines

    An illustrated history of some of the most popular branded medicines. Includes colourful historical adverts and details of the medicine's formula and intended purpose.

    £22.00Buy now
  • International Research in Healthcare

    International Research in Healthcare

    Guidance for students or researchers undertaking a multi-centre research project in health services, medicines use and professional practice.

    £38.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.